Mouse anti-Human LAG3 Monoclonal Antibody | anti-LAG3 antibody

LAG3

Cat. Num. AAA344138

• Reactivity: Human
• Synonyms: LAG3; Monoclonal Antibody; anti-LAG3 antibody

• Host: Mouse
• Reactivity: Human
• Clonality: Monoclonal
• Isotype: IgG2b, kappa
• Form/Format: Tris Buffer, pH 7.3 - 7.7, with 1% BSA and <0.1% Sodium Azide

• Application Notes: 1:200
• Positive Control: Tonsil
• Localization: Cytoplasmic, Membranous
• Principles and Procedures: Visualization of the antigen present in tissue sections is accomplished in a multi-step immunohistochemical staining process, in conjunction with a horseradish peroxidase (HRP) or alkaline phosphatase (AP) linked detection system. The process involves the addition of the stated antibody (primary antibody) to a tissue slide, followed by a secondary antibody (linked to an enzyme complex) which specifically binds to the primary antibody. A chromogenic substrate is then added which reacts with the enzyme complex, resulting in a colorimetric reaction at the site of the antigen. Results are interpreted using a light microscope.
• Preparation and Storage: Store at 2-8 degree C.; To ensure stability, immediately replace vial back in the refrigerator after each use. When stored correctly, the antibody is stable until the expiry date indicated on the label.

Immunohistochemistry (IHC)

(LAG3 on Tonsil)

Related Product Information for anti-LAG3 antibody

LAG3 (Lymphocyte-activation gene 3) was discovered in 1990 and was previously designated as CD223. LAG3 is a cell surface molecule expressed by activated T cells, natural killer cells, B cells and plasmacytoiddendritic cells. It binds to major histocompatibility complex (MHC) class II molecules and serves as an immune checkpoint receptor. LAG3 negatively regulates cellular proliferation, activation and homeostasisof T cells, and plays a role in Treg suppressive function. LAG3 also helps maintain CD8+ T cells in atolerogenic state and, working with PD-1, helps maintain CD8 exhaustion during chronic viral infection. LAG3 expression was detected in tumour infiltrating lymphocytes. IHC revealed LAG3 expression was distributed on lymphocytes scattered in renal cell carcinoma, melanoma and lymphomas. They were also detected in the tumour stroma as well as in the peritumoral tissue. LAG3 is the target of various drug development programs for cancer and autoimmune disorders. In soluble form, it is also being developed as a cancer drug in its own right.